Sort   by:  
 Page size 
UnknownTime to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
Not available
S-EPMC9843193 | biostudies-literature
UnknownWhat Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
Not available
S-EPMC8596929 | biostudies-literature
UnknownSustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
Not available
S-EPMC10070065 | biostudies-literature
UnknownSafety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
Not available
S-EPMC4919033 | biostudies-literature
UnknownTargeting DORIS Remission and LLDAS in SLE: A Review.
Not available
S-EPMC10654283 | biostudies-literature
UnknownFully automated joint space width measurement and digital X-ray radiogrammetry in early RA.
Not available
S-EPMC5574453 | biostudies-literature
UnknownPretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Not available
S-EPMC4431327 | biostudies-literature
UnknownA Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
Not available
S-EPMC5656933 | biostudies-literature
UnknownEvaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
Not available
S-EPMC6593802 | biostudies-literature
UnknownCirculating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis.
Not available
S-EPMC11667770 | biostudies-literature
Sort   by:  
 Page size